期刊文献+

CT引导下经皮穿刺植入放射性^(125)I粒子治疗肺癌的临床应用 被引量:1

Clinical application of ^(125)I seed implantation in lung carcinoma guided by CT
下载PDF
导出
摘要 目的探讨CT引导下经皮穿刺植入放射性125I粒子的肺癌治疗方法,观察临床疗效和不良反应。方法于2004年6月-2005年10月,经CT引导125I粒子植入治疗肺癌32例。所有病例均行术前TPS制定治疗计划,术后质量验证。全部患者均植入0.5mCi-1.0mCi的放射性粒子,12-60颗。结果植入病例全部成功,无死亡,部分出现气胸、出血,术后1周复查外周血象、1月复查CT及临床观察无毒副反应,术后定期复查CT,未出现放射损伤症状,未发现粒子脱落或游走等并发症。CR22.58%、PR61.29%、SD12.9%、PD3.2%。中位生存期大于12个月。结论CT引导下经皮穿刺放射性125I粒子近距离照射治疗肺癌安全、有效,并且创伤小、并发症少。 Objective To explore the therapy method of ^125I seed implantation in hmg careinorma guided by CT and to observe the clinical effect and adverse response. Methods From June, 2004 to October, 2005, 32 patients with lung carcinoma accepting CT guided radioactive seed ^125I implanlation were enrolled in this study. All cases were performed according to the treatment planning system (TPS) before, operation, then the radioactive dose was validated, Every patient was implanted into radioactive seed of 0.5 mci - 1.0 mci in does and 12 - 60 in quantities. Results All implantation cases were satisfaetive, no death occurred, but pnevanothorax and blooding in partial cases. There is no toxic l'espense in reexamination of peripheral blood hemogram one week after treatment, of CT one month after operation and clinical observation; whereas periodic CT found no symptom of radioactive trauma and no complication of dropping, migrating and so on. Among lung carcinoma in 32 patients, 22.58% obtained CR, 61.29% obtained PR, 12.9% CD and 3.2% PD. Mediam survival time (MST) was more than 12 months. Conclusion The brachytherapy of ^125I seed implantation in lung carcinoma guided by CT is safe and effective, with less traumas and complications.
出处 《实用肿瘤学杂志》 CAS 2006年第5期386-388,共3页 Practical Oncology Journal
关键词 ^125I粒子 近距离照射 肺癌 CT 植入 ^125I seed Implantation Lung carcinonna CT Brachytherapy
  • 相关文献

参考文献6

二级参考文献19

  • 1Lazarescu GR, Battista JJ. Analysis of the radiobiolo gy of Ytterbium-169 and Iodine-125 permanent brachytherapy implants[j]. Phys Med Biol, 1997,42:1727-1736.
  • 2Ling CC. Permanent implams using Au-198, Pd-103and I-125: Radiobiological considerations based on the linear quadratic model [J]. Int J Radiat Oncol Biol Phys, 1992,23:81-87.
  • 3Kim JH, Hilaris BS. Iodinc-125 sourcc in interstitial tumor therapy[J]. Radiology, 1975,123:163-169.
  • 4Anderson LL, Kuan HM, Ding IY. Clinical dosimetry with I-125 [A]. In Gorge [ed]. Modern interstitial and intracavitary radation cancer management [C].New York : Masson Publishing, 1981.
  • 5Williamson JF. Physics of brachythcrapy[A]. Perez CA, Brady LW[ed]. Principles and practice of radiation oncology [C]. Third Edition, Philadelphia: Lippincott -Raven, 1997.
  • 6Nath R, Anderson LL, Meli JA, et al. Code of practice for brachytherapy physics: Report of the AAPM radation therpy committee task group NO. 56[J]. Med Phys, 1997,24:1557-1579.
  • 7Wu A, Zwicker D, Sternick ES. Tumor dose specification of I-125 seed implants[J]. Med Phys, 1985,12:27-31.
  • 8Chen Y, Stanton RE, Holst RJ, et al. Treatment planning for prostate implant with loose seeds [J].Med Phys,1997, 24:1141-1145.
  • 9Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachtherapy sources:Recommendations of the AAPM radiation therapy committee task group NO. 43[J]. Med Phys,1995, 22:209-233.
  • 10Williamson JF, Courscy BM, DeWerd LA, et al.Guidence to users of Nycomed Amersham and North American Scientific, Inc, I-125 interstitial sources:Dosimetry and calibration changes: Recommendations of the American Association of physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on low-energy[J]. Med Phys, 1999,26:570-573.

共引文献99

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部